Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (215)

101

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma : final results from the phase 2 GEN501 and SIRIUS trials

enthalten in: The Lancet. Haematology | 2020

von Usmani, S. | Nahi, H. | Plesner, T. | +13

CommentIn: Lancet Haematol. 2020 Jun;7(6):e426-e427. - PMID 32470429

102

Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients

enthalten in: Haematologica | 2020

von Frerichs, K. | Bosman, P. | van Velzen, J. | +8

103

Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Frerichs, K. | Broekmans, M. | Marin Soto, J. | +14

104

Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma

enthalten in: Journal of clinical medicine | 2020

von Franssen, L. | Stege, C. | Zweegman, S. | +2

105

Targeted Therapy With Immunoconjugates for Multiple Myeloma

enthalten in: Frontiers in immunology | 2020

von Bruins, W. | Zweegman, S. | Mutis, T. | +1

106

Editorial : Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches

enthalten in: Frontiers in oncology | 2020

von van de Donk, N. | Kastritis, E. | Gay, F.

107

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

enthalten in: Haematologica | 2020

von Holthof, L. | van der Horst, H. | van Hal-van Veen, S. | +11

108

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment

enthalten in: Frontiers in oncology | 2020

von van der Schans, J. | van de Donk, N. | Mutis, T.

109

CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients

enthalten in: Journal of translational autoimmunity | 2019

von Frerichs, K. | Verkleij, C. | Bosman, P. | +3

110

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

enthalten in: Blood | 2019

von Usmani, S. | Nahi, H. | Mateos, M. | +13